Hawaii Biotech to Relocate to Dole Cannery - 11 Dec 2015

Hi, Biotech is an independent publication with no affiliation with Hawaii Biotech, Inc. This page preserves a historical record from the company's original press archive, republished for research and archival purposes. Copyright in the original material remains with its original owner.

HAWAII BIOTECH TO RELOCATE TO DOLE CANNERY

FOR IMMEDIATE RELEASE Contact: Dr. Elliot Parks, 808-792-1399 eparks@hibiotech.com

(Honolulu, Dec. 11, 2015) -- Hawaii Biotech, Inc., Honolulu's oldest biotech company, has signed a five-year lease with Castle & Cooke for 10,835 square feet of space on the second floor of Dole Cannery. The vaccine and drug research and development company has been located in Aiea since 1983 in the former Sugar Planters Association building. The building was sold to Clinical Laboratories of Hawaii in 2014.

"We're very pleased with the space at Dole Cannery. The building has some significant attributes that we were looking for, including high ceilings that can accommodate our mechanical equipment, and the staff really appreciates the natural light and the convenient location," said president and chief executive officer Elliot Parks, Ph.D.

KYA Design Group of Honolulu has been contracted for design and development, with assistance from Ferguson Pape Baldwin Architects of San Diego for their expertise in laboratory planning and design. The general contractor is Arita-Poulson General Contracting, also of Honolulu. Tenant improvements are underway.

Hawaii Biotech's foundations in tropical medicine led the company to become a leading developer of protective vaccines and more recently drug development, specifically the development of anti-toxin drugs to help protect first responders from potential acts of terrorism.

Hawaii Biotech does not use infectious viruses or toxins, but rather bases its product development on recombinant proteins and synthetic molecules.

About Hawaii Biotech, Inc. (HBI): Hawaii Biotech is a privately held biotechnology company focused on the development of prophylactic vaccines for established and emerging infectious diseases and anti-toxin drugs for biological threats. HBI has developed proprietary expertise in the production of recombinant proteins that have application to the manufacture of safe and effective vaccines, diagnostic kits, and as research tools. The company has developed a product pipeline of recombinant subunit vaccines, including vaccine candidates for dengue fever, West Nile virus, tick-borne flavivirus, malaria, Crimean-Congo hemorrhagic fever, and Ebola. HBI completed successful first-inhuman Phase 1 clinical studies with both West Nile virus and dengue vaccines in healthy human subjects. The company is also continuing the development of small molecule anti-toxin drugs for anthrax and botulism. HBI, founded in Hawaii in 1982, is currently headquartered in suburban Honolulu. For more information, please visit: www.hibiotech.com

- 1 of 1 -